It was about a year ago when we first started exploring the world of legal cannabis investing.
We've followed U.S. Attorney General Jeff Sessions' go-nowhere "war against cannabis" – and President Donald Trump's essential "green light" for medical marijuana. And we've watched legalization efforts in the United States and Canada.
It was also about a year ago that I first published my "weed investors' bible" – The Roadmap to Marijuana Millions. At the time, it was packed with 30 of my absolute favorite plays in the still-booming legal cannabis sector.
Since then, weed investing's only gotten bigger, better, and more profitable.
Over the past year, this section of my Nova-X Report portfolio has seen 10 double-digit winners and eight triple-digit winners… 291% gains… 193.3%… 189.5%…
One recommendation even saw peak gains of 1,588%.
In other words, if you're a Nova-X subscriber who jumped in when I released The Roadmap, you've likely made a mint. And you've probably kept a mint, too, if you closely follow my recommended "free trade" strategy of taking your initial stake off the table and playing with the "house money" every time a stock hands out 100% gains.
Now we want to see what's coming just around the corner.
I expect four watershed events in marijuana investing – four big catalysts… "triggers" – to happen over the next 365 days.
So let's take a look at exactly where I think the biggest profits of 2018 will come from in our "second season" of legal cannabis investing…
4 Cannabis Stock Triggers for the Next 12 Months
My team and I just finished up "Phase II" of The Roadmap to Marijuana Millions. It's already gotten Nova-X Report readers headed into the next year with the latest updated information on the best cannabis investments in biotech/pharma, recreational and medicinal retail, distribution, edibles, and more.
What's more, it's full of the latest word on the huge regulatory happenings at the state and federal levels that I believe will really "trigger" pot stocks to take off (even more than they already have).
I'm sharing these predictions with you folks today for the same reason I've shared some of my best weed investing recommendations: The profit potential is enormous.
And I want to make sure everyone has the chance to deploy their capital before these upcoming events – these catalysts – come to pass.
We're looking at some massively profitable outcomes here…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.